(VIANEWS) – SANOFI (SAN.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| SANOFI (SAN.PA) | €90.96 | 3.6% | 5.82% |
| IPSEN (IPN.PA) | €110.30 | 1.11% | 17.91% |
| VIRBAC (VIRP.PA) | €346.00 | 0.38% | 13.84% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. SANOFI (SAN.PA)
3.6% Forward Dividend Yield and 5.82% Return On Equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €90.96 at 07:30 EST, way below its 52-week high of €106.14 and way higher than its 52-week low of €80.60.
Volume
Today’s last reported volume for SANOFI is 1839940 which is 37.38% above its average volume of 1339290.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 5.2% and positive 0.8% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SANOFI’s stock is considered to be oversold (<=20).
More news about SANOFI.
2. IPSEN (IPN.PA)
1.11% Forward Dividend Yield and 17.91% Return On Equity
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Earnings Per Share
As for profitability, IPSEN has a trailing twelve months EPS of €7.4.
PE Ratio
IPSEN has a trailing twelve months price to earnings ratio of 14.91. Meaning, the purchaser of the share is investing €14.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.91%.
Yearly Top and Bottom Value
IPSEN’s stock is valued at €110.30 at 07:30 EST, way below its 52-week high of €130.70 and way higher than its 52-week low of €99.70.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 3.44B for the twelve trailing months.
Volume
Today’s last reported volume for IPSEN is 106351 which is 33.58% above its average volume of 79614.
Volatility
IPSEN’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.64%, a positive 0.18%, and a positive 1.17%.
IPSEN’s highest amplitude of average volatility was 1.66% (last week), 1.02% (last month), and 1.17% (last quarter).
More news about IPSEN.
3. VIRBAC (VIRP.PA)
0.38% Forward Dividend Yield and 13.84% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.84%.
Moving Average
VIRBAC’s worth is higher than its 50-day moving average of €345.60 and higher than its 200-day moving average of €344.07.
Volatility
VIRBAC’s last week, last month’s, and last quarter’s current intraday variation average was 2.35%, 0.30%, and 1.67%.
VIRBAC’s highest amplitude of average volatility was 2.54% (last week), 1.55% (last month), and 1.67% (last quarter).
Yearly Top and Bottom Value
VIRBAC’s stock is valued at €346.00 at 07:30 EST, under its 52-week high of €377.50 and way above its 52-week low of €239.00.
More news about VIRBAC.
